ROMITO, Marianna, JUILLERAT, Alexandre, KOK, Yik Lim, HILDENBEUTEL, Markus, RHIEL, Manuel, GEOFFROY, Andrieux, GEIGER, Johannes, RUDOLPH, Carsten, MUSSOLINO, Claudio, DUCLERT, Aymeric, METZNER, Karin J., DUCHATEAU, Philippe, CATHOMEN, Anton und CORNU, Tatjana I., 2020. Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection. Freiburg: Universität.

Romito, M., Juillerat, A., Kok, Y.L., Hildenbeutel, M., Rhiel, M., Geoffroy, A., Geiger, J., Rudolph, C., Mussolino, C., Duclert, A., Metzner, K.J., Duchateau, P., Cathomen, A., Cornu, T.I., 2020. Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection. Universität, Freiburg. https://doi.org/10.1002/biot.202000023

Romito, M., Juillerat, A., Kok, Y. L., Hildenbeutel, M., Rhiel, M., Geoffroy, A., Geiger, J., Rudolph, C., Mussolino, C., Duclert, A., Metzner, K. J., Duchateau, P., Cathomen, A., & Cornu, T. I. (ca. 2020). Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection [Cd]. Universität. https://doi.org/10.1002/biot.202000023

Romito M, Juillerat A, Kok YL, Hildenbeutel M, Rhiel M, Geoffroy A, Geiger J, Rudolph C, Mussolino C, Duclert A, Metzner KJ, Duchateau P, Cathomen A, Cornu TI (2020) Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection. Universität, Freiburg

Romito, Marianna/ Juillerat, Alexandre/ Kok, Yik Lim/ Hildenbeutel, Markus/ Rhiel, Manuel/ Geoffroy, Andrieux/ Geiger, Johannes/ Rudolph, Carsten/ Mussolino, Claudio/ Duclert, Aymeric/ Metzner, Karin J./ Duchateau, Philippe/ Cathomen, Anton/ Cornu, Tatjana I., Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection, Freiburg 2020.